Key Insights

Highlights

Treatment Research

2 treatments under study, led by Vactosertib

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06044311Phase 2Recruiting

Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma

Showing all 1 trials

Research Network

Common Treatments

  • Vactosertib1
  • Standard Of Care Preoperative Therapy1

Active Sponsors

  • Melissa Lumish1

Top Investigators

  • Melissa Lumish, MD1

    University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Related Conditions

  • Siewert Type Ii Adenocarcinoma Of Esophagogastric Junction1
  • Adenocarcinoma Esophagus1
  • Siewert Type I Adenocarcinoma Of Esophagogastric Junction1

Activity Timeline